Fallopian Tube Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Phase II Study of Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Condition: PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment Intervention: Drug: Orevogomab+PLD Sponsor: Yonsei University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2022 Category: Research Source Type: clinical trials
Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial
Condition: Ovarian Cancer Interventions: Drug: albumin-bound paclitaxel; Drug: paclitaxel Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 7, 2022 Category: Research Source Type: clinical trials
